Voya Investment Management LLC Sells 3,803 Shares of MiMedx Group, Inc $MDXG

Voya Investment Management LLC reduced its stake in MiMedx Group, Inc (NASDAQ:MDXG) by 10.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 32,768 shares of the company’s stock after selling 3,803 shares during the period. Voya Investment Management LLC’s holdings in MiMedx Group were worth $249,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Rhumbline Advisers increased its holdings in shares of MiMedx Group by 1.4% in the 1st quarter. Rhumbline Advisers now owns 177,156 shares of the company’s stock worth $1,346,000 after buying an additional 2,436 shares during the last quarter. Strs Ohio bought a new stake in shares of MiMedx Group in the 1st quarter worth about $595,000. Jacobi Capital Management LLC increased its holdings in shares of MiMedx Group by 24.6% in the 1st quarter. Jacobi Capital Management LLC now owns 36,725 shares of the company’s stock worth $279,000 after buying an additional 7,250 shares during the last quarter. Focus Partners Wealth bought a new stake in shares of MiMedx Group in the 1st quarter worth about $128,000. Finally, Goldman Sachs Group Inc. increased its holdings in shares of MiMedx Group by 22.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,121,814 shares of the company’s stock worth $8,526,000 after buying an additional 207,397 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors.

MiMedx Group Price Performance

MiMedx Group stock opened at $6.93 on Tuesday. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of 33.00 and a beta of 1.74. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.39 and a quick ratio of 3.90. MiMedx Group, Inc has a 1 year low of $5.47 and a 1 year high of $10.14. The firm has a 50-day moving average of $7.05 and a two-hundred day moving average of $6.88.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.04. MiMedx Group had a net margin of 8.84% and a return on equity of 23.03%. The firm had revenue of $98.61 million for the quarter, compared to the consensus estimate of $90.79 million. On average, research analysts forecast that MiMedx Group, Inc will post 0.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on MDXG shares. Cantor Fitzgerald boosted their target price on shares of MiMedx Group from $11.00 to $12.00 and gave the stock an “overweight” rating in a report on Thursday, July 31st. Wall Street Zen upgraded shares of MiMedx Group from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 2nd. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, MiMedx Group presently has an average rating of “Buy” and a consensus price target of $12.00.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.